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Review Abstract
The spleen is a major site for extramedullary hematopoiesis and adult mouse and human spleens retain low numbers 
of hematopoietic stem cells (HSC). Hematopoiesis is however dependent on stromal microenvironments that provide 
appropriate molecular signals. Recent evidence now suggests that a distinct stromal cell type exists in the spleen which 
can function as a niche for hematopoiesis. This review considers the role of the spleen in hematopoiesis, and the pos-
sibility that the spleen can be utilized or amplified as a site for hematopoiesis during HSC transplantation. If stromal 
cells can be isolated and used to expand HSC in vitro, or provided as an ectopic niche in vivo for the same purpose, then 
the potential exists to enhance hematopoiesis in patients undergoing myeloablative treatment, HSC transplantation or 
involution of lymphoid tissue with ageing.  
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Introduction
Bone marrow (BM) is a rich source of HSC and for 
decades bone marrow transplants have provided 
HSC for regeneration of the hematopoietic sys-
tem in humans. HSC arise in the embryo from an 
hemangioblast present in the yolk sac and aorta-
gonad-mesonephros. They then appear in the fetal 
liver and spleen, entering the bone marrow at a 
late stage during embryogenesis. They are main-
tained for life in BM, spleen and liver of mice (1), 
and have been detected in BM and spleen of adult 
humans (2). HSC have distinguishing properties of 
self-renewal, asymmetric cell division, and ability to 
clonally regenerate all hematopoietic cell types (3). 
The methodology for sorting HSC from BM using 
specific antibodies and flow cytometry has become 
a standard technique in many labs (4, 5). The HSC 
subset is however heterogeneous, comprising cells 
with long term and short term reconstitution ca-
pacity (6, 7). Longterm HSC are commonly isolated 
from mouse BM or spleen as lineage (Lin)-Sca-1+c-
kit+Flt3- cells (6), and can be further purified as the 
CD150+CD48- subset of Lin-Sca1+ckit+ BM (8, 9). Epi-
genetic imprinting of HSC also contributes to dif-
ferences in hematopoietic potential (10). Given the 
level of heterogeneity amongst HSC, it is important 
to consider them in relation to their niche of origin, 
their distinct hematopoietic potential, and to use 
this knowledge to inform HSC transplantation in 
the clinic. Most studies have concentrated on the 
more prevalent HSC in BM with less attention given 
to HSC in extramedullary sites like spleen or liver. 
While hematopoietic niche elements in BM have 
been defined as osteoblasts, endothelial cells and 
perivascular reticular cells, there has been little 
consideration of the stromal elements which form 
niches for HSC in the spleen. Former work from this 
lab has identified a unique stromal cell type which 
supports hematopoiesis in vitro from overlaid HSC. 
Based on this finding, the hypothesis is advanced 
that the spleen contains a unique mesenchymal 
cell type which independently functions as a niche 
for HSC, supporting HSC maintenance, self-renewal 
and differentiation. Another hypothesis is that pro-
genitors of these stromal cells could seed ectopic 
niches for long-term support of hematopoiesis. 
Artificial or ectopic lymph nodes have been de-
veloped with biocompatible scaffolds supporting 
tissue formation. However, extension of that tech-
nology into the splenic model will be entirely de-
pendent on identification of the appropriate stro-
mal cells, or their progenitors, to seed scaffolds.
The Spleen in Hematopoiesis
Spleen is a secondary lymphoid organ essential 
for T and B cell immunity to blood-borne anti-
gens. While neonatally splenectomised mice were 
once thought to display apparently normal he-
matopoietic development, a specific role for the 
spleen in immunity is demonstrated by evidence 
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that asplenic humans have enhanced susceptibility to infection 
with encapsulated bacteria such as Streptococcus (11). Its impor-
tance in immunity can be demonstrated following splenectomy 
in humans. Subsequent autotransplantion of the spleen onto 
the omentum has been shown to preserve splenic immune func-
tion (12). The fact that transplanted spleen fragments can regen-
erate by reforming stromal cell networks and filling with lymphoid 
and other hematopoietic cells, (13) recommends the spleen in 
humans as an important target in regenerative medicine. Most 
studies on the role of the spleen in extramedullary hematopoi-
esis have involved the murine model. While the human spleen 
is functionally similar in terms of immune cell development, the 
marginal zone surrounding the white pulp region is structurally 
distinct from murine spleen (14). In the human spleen, an inner 
and outer marginal zone is surrounded by a large perifollicular 
zone which separates the follicular marginal zone from the red 
pulp. This forms part of the open circulation of the spleen and 
lymphocytes enter the white pulp without crossing an endothe-
lial layer. Rodents have a marginal sinus that separates the mar-
ginal zone from the follicles, and lymphocytes enter the spleen 
through the marginal sinus where they bind to endothelial cells 
and migrate across the marginal zone. Despite these differences, 
human and murine spleens contain many equivalent lymphoid, 
myeloid and stromal cell types, and demonstrate similar immune 
functional potential. 
An historical view is that the spleen contributes mainly to ery-
throid cell development, undergoing hematopoiesis only at 
times of stress or myeloablation (15). The spleen microenviron-
ment also supports the later development of myeloid and den-
dritic cells, such that subsets like plasmacytoid dendritic cells 
(DC), conventional DC and monocytes develop from BM-derived 
precursors entering the spleen from blood (16). The spleen is now 
recognized to be an important site for extramedullary hemato-
poiesis, and small numbers of HSC can migrate through blood 
and lymph entering the spleen, and other tissues like the liver, 
lung and brain (17). The number of migrating HSC increases fol-
lowing acute inflammation or drug treatment which induces 
their mobilization (18, 19). Adult mice have been found to retain 
primitive longterm reconstituting HSC in the spleen and liver, al-
beit in far lower numbers than in bone marrow (1, 20). Similarly, 
low numbers of hematopoietic stem/progenitor cells (HSPC) 
were recently detected in adult spleens of pigs, baboons and hu-
mans (2). Spleens of mice and humans therefore retain low num-
bers of HSC and represent appropriate microenvironments for 
extramedullary hematopoiesis at least under conditions of stress 
or inflammation. 
A related issue is whether the spleen in the resting state main-
tains endogenous HSC which self-renew and differentiate within 
the spleen, and contribute to steady-state hematopoiesis. In-
deed, HSC in murine spleen reflect multipotent longterm self-
renewing stem cells similar to those found in BM (1, 20). In re-
constitution studies in mice, splenic HSC gave full hematopoietic 
reconstitution of myeloid, dendritic and lymphoid cells for up to 
51 weeks post transplantation (20). Recently, a single stromal cell 
type was isolated from murine spleen that was shown to support 
HSC self-renewal and differentiation in vitro (21, 22). This finding 
invokes a model whereby spleen stromal cells maintain endog-
enous hematopoietic progenitors that undergo myelopoiesis in 
vitro to produce a tissue-specific antigen presenting cell (named 
L-DC) (23-25). The in vivo equivalent of this subset has since been 
identified as a novel subset of myeloid dendritic-like cells in the 
spleen distinct from other known DC and myeloid subsets (26). 
The spleen thus appears to contribute in a tissue-specific man-
ner to hematopoiesis in the resting state. The finding that the 
spleen supports development of a novel antigen presenting cell 
type unique to the spleen is not without precedence, and tissue-
specific antigen presenting cells have been described previously 
in skin (27) and brain (28), supporting the compartmentalisation 
of the immune system.
When spleen-derived HSC were used to reconstitute irradiated 
host mice, they were found to have different hematopoietic po-
tential from BM-derived HSC, producing higher relative numbers 
of L-DC compared with other subsets of dendritic and myeloid 
cells (20, 29). While others have reported equal reconstitution 
potential for both spleen- and BM-derived HSC, those studies 
did not compare the development of individual DC/myeloid 
subsets (30). The hematopoietic potential of HSC may therefore 
differ with tissue origin, such that the spleen can generate cells 
not produced within the BM microenvironment. This could be a 
property endogenous to the stem cell, or could be imprinted by 
the microenvironment in which HSC develop. 
Stromal Cell Niches Support Hematopoiesis
In BM, stromal cells regulate hematopoiesis by providing struc-
tural support through a network of connective tissue of mesen-
chymal, and more specifically, osteoblastic and endothelial ori-
gin. Stromal niches support the maintenance and self-renewal of 
HSC, and the differentiation and lineage commitment of hemato-
poietic progeny (31). Cell contact between HSC and stromal cells 
is essential, and hematopoiesis is mimicked only poorly in vitro by 
cocktails of soluble factors (32). The niche provides essential sig-
nals for HSC maintenance and self-renewal. The Hedgehog, Wnt 
and Notch pathways are known regulators of HSC self-renewal, 
and bone morphogenic protein 4, transforming growth factor-b 
and stem cell factor also support HSC development (33). Essen-
tial niche elements have been described as osteoblastic in BM, 
vascular or endothelial in BM and the spleen (8, 34, 35), and more 
recently as perivascular in BM, comprising distinct mesenchymal 
progenitor cells (36). During HSC mobilization, endothelial cells 
in or near sinusoidal vessels in BM release developing stem cells 
into blood (8). Similarly, engraftment of HSC into the spleen oc-
curs in contact with sinusoidal venous endothelium (8). 
Most studies on hematopoiesis have investigated osteoblastic 
niches in BM, and vascular or perivascular niches are not well de-
scribed. Osteoblastic niches are characterised by the expression 
of osteopontin, osterix, N-cadherin and tie-2; (37, 38) all known 
regulators of hematopoiesis. The importance of bone-forming 
cells in hematopoiesis is supported by evidence that ectopic HSC 
niches form under the kidney capsule of mice upon transplanta-
tion with either subendothelial stromal cells from BM, or a subset 
of fetal bone cells (38, 39). These ectopic niches recruit HSC and 
endothelial cells, and maintain longterm HSC for 4-5 weeks. En-
dochondreal ossification or bone formation appears to be neces-
sary for formation of a vascularised niche in bone (38). In contrast, 
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hematopoiesis in the spleen, fetal liver and other extramedullary 
sites occurs in the absence of bone-forming osteoblastic cells. An 
important question is whether signals for vascularisation, and for 
HSC maintenance and self-renewal, are provided by a distinct 
stromal cell type in these tissues. Another consideration is wheth-
er HSC in non-bone-forming tissues represent a distinct subset 
with different signalling requirements for their differentiation.
There is now increasing support for the role of perivascular stro-
mal cells in HSC development in the BM of both mice and humans 
(36). These distinct cells have been termed variably adventitial re-
ticular cells (ARC), mesenchymal stem cells or osteoprogenitors in 
humans (39). In mice, they have been described as CXCL12-abun-
dant reticular (CAR) cells (40). In humans, they have been aligned 
with pericytes or mural cells which surround the vascular endotheli-
um (41), and reflect multipotent osteoprogenitors with osteogenic 
and adipogenic differentiative potential (42). Recently they were 
described as Leptin receptor-expressing perivascular stromal cells, 
which, together with endothelial cells, provide an essential source 
of stem cell factor for HSC development (43). This cell type in BM 
appears to be heterogeneous, but equivalent or similar cells have 
not yet been described in the spleen. 
Characterisation of Splenic Stroma That Support 
Hematopoiesis
Stromal cell components of lymphoid tissues have been difficult 
to characterise in the absence of definitive cell surface markers, 
and most studies have involved cultured stromal cell lines rather 
than freshly isolated cell subsets. While murine fetal liver stromal 
lines can support HSC maintenance in vitro (44, 45), BM stromal 
lines have been disappointing as niche models, but this could re-
flect the low frequency of competent stromal cells in BM. Splenic 
stromal lines that support HSC maintenance and myelopoiesis in 
vitro can be readily isolated from longterm stroma-dependent 
spleen cultures which also support continuous in vitro hemato-
poiesis (23, 46). The STX3 line, and its cloned derivatives, was first 
characterised as an atypical or immature endothelial cell type 
in mice (22). STX3 cells produce high levels of CXCL12, a factor 
that recruits HSC into BM niches, (40, 47) and expresses markers 
common to endothelial cells like CD90, CD34, COL18a1, CD164, 
FLT1, MCAM and VCAM, although not CD31, a marker of mature 
vascular endothelial cells (21, 48). STX3 clones such as 5G3, 2A8, 
10C9 and 3B5 have endothelial-like morphology, and all but 3B5 
support hematopoiesis in BM overlaid above stroma (22).
STX3 co-cultures of lineage-depleted BM cells, or purified BM-
derived HSC, now provide a direct test of the hematopoietic sup-
port capacity of splenic stromal cell lines (24, 49). The cell type 
produced in co-cultures over the 5G3 clone of STX3 resembles 
the L-DC subset of antigen presenting cells described previously 
as endogenous to the spleen (26). Similarly, Lin-ckit+ HSPC iso-
lated from the spleen were found to colonise 5G3 co-cultures 
for longterm production of L-DC (25). Equivalent human spleen 
stromal lines have now been derived from splenic LTC. These re-
semble the murine lines and appear to support the production 
of cells resembling L-DC from overlaid BM cells (data in prepara-
tion). Indeed, there appears to be similarity between human and 
murine spleens in that they harbor HSC, and contain stromal cells 
that support hematopoiesis. While the murine model is more 
amenable to study, follow-on human studies appear feasible. 
While HSC have been localized in murine spleen in contact with 
sinusoids in the red pulp area (8), it is not known how those 
niches contribute to hematopoiesis, or the nature of any stromal 
cell types involved. While osteoprogenitors are essential for the 
establishment of HSC niches in BM, HSC also develop in the em-
bryo, and in the adult spleen and liver, in the apparent absence of 
osteogenesis. While secondary lymphoid tissues have been well 
characterised in terms of mature stromal cell components and 
their role in lymphopoiesis, the role of stromal cells in extramed-
ullary hematopoiesis has not been documented. Splenic stroma 
represents a mixed population including vascular and lymphatic 
endothelial cells, marginal zone macrophages, follicular DC, fi-
broblastic reticular cells, marginal reticular cells and red pulp 
fibroblasts (50, 51). However, the location of any mesenchymal 
stem/progenitor cells, or indeed osteogenic or endothelial pro-
genitor cells, has not yet been investigated in the spleen. While 
markers of mesenchymal cells are known, most are not unique 
to one cell type and may also be expressed by hematopoietic or 
endothelial cells. The expression of markers common to STX3 and 
its cloned lines could be used to benefit the characterization and 
isolation of stromal cell fractions for further study. Any subsets of 
interest could also be functionally assessed for their in vitro he-
matopoietic support capacity for production of L-DC. 
Production of Ectopic Splenic Niches or Artificial Spleens
If stromal cells supporting hematopoiesis in the spleen can be 
identified and isolated, then it should be possible to reengineer 
the spleen microenvironment for enhanced hematopoietic out-
put. Previous work with long-term spleen cultures and stromal 
co-cultures support a niche model involving only one stromal 
cell type. One possibility is that HSC numbers could be amplified 
ahead of transplantation by culture above competent stroma. An-
other approach is to expand the niche space for hematopoiesis. 
Ectopic splenic niches can be established under the kidney cap-
sule of mice following transplantation of spleen capsules, spleen 
fragments, or in vitro grown stromal cells embedded in collagen 
sponges (13, 52, 53). The subcapsular region of the kidney has 
proven a successful site for transplantation due to its high vas-
culature, and because the kidney contains no HSC (38). Neonatal 
7-day spleen fragments engrafted under the kidney capsule of 
splenectomised mice showed reconstitution with donor type he-
matopoietic cells (52). Grafts retained donor-type HSC, evident by 
development of donor-type myeloid cells over 2 to 4 weeks. Host 
type HSC, lymphocytes and myeloid cells were also recruited into 
grafts (52). Others have reported engraftment and reconstitution 
of irradiated adult and neonatal spleen for up to 3 months, al-
though that model could not assess hematopoiesis arising from 
endogenous HSC (54). Ideally, ectopic niches could be generated 
using isolated splenic stromal cells embedded in artificial matri-
ces as a support structure for tissue formation. Indeed, advances 
have already been made with the synthesis of artificial lymph 
nodes (55, 56) and the spleen (57), where biocompatible scaf-
folds support ectopic tissue formation. A number of studies sup-
port a deterministic role for a single splenic stromal cell type in 
the formation of HSC niches in the spleen. The lineage origin of 
those stromal cells as endothelial or mesenchymal cells, and their 
status as mature cells versus progenitors, is not yet clear. Their 
relationship with similar niches in BM is also unknown. The ability 
of candidate stromal cells to successfully form an ectopic niche 
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would depend on the formation of a vascular network and their 
ability to maintain HSC and support hematopoiesis. 
One hypothesis is that the spleen maintains a progenitor popu-
lation that seeds the formation of stroma constituting the HSC 
niche. Another is that these are readily isolated as constituents 
of blood or BM. There have been several reports of potential en-
dothelial progenitors in cord blood, fetal blood, peripheral blood 
(58, 59) and also adult BM (60). Mesenchymal stem/progenitors are 
also present in BM and enter blood upon mobilization of BM stem 
cells (61). Indeed, progenitors would represent important candi-
dates for the establishment of long-term ectopic niches in patients 
through their capacity to continuously regenerate stroma. 
Conclusion
Demonstration that artificial hematopoietic niches can be estab-
lished in vivo, become colonized by HSC and then support he-
matopoiesis, would represent significant advances. Successful 
production of artificial or ectopic spleens however depends on 
the isolation and transplantation of splenic stromal cells which 
support hematopoiesis. The challenge therefore exists to identify 
the mesenchymal or endothelial progenitors in the spleen, blood 
and BM that give rise to stromal cells, and so regenerate hemato-
poietic niches in the spleen and other organs. If stromal cells or 
their progenitors can be harvested for engraftment of ‘artificial 
niches’ ahead of HSC transplantation, then this type of stem cell 
therapy could have considerable significance for enhancement 
of hematopoiesis in HSC transplant patients. 
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